MediciNova Inc (MNOV) shareholders
Close on Nov 17, 2026Market cap $65.96MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| 3D Investment Partners Pte. Ltd. Joint filing with 3D Opportunity Master Fund (9.90%) | 4,862,047 | 9.90% | 13D (active) amendment | Sep 25, 2026 |
| Vanguard Capital Management Joint filing with Vanguard Morningstar Total Stock Market Index Fund (5.37%) | 3,548,731 | 7.20% | 13G (passive) | Sep 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MNOV | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Essex Woodlands Management, Inc. | 1,105,941 | 2.25% | $1.46M | – | 0.57% |
| BlackRock, Inc. | 752,091 | 1.53% | $992.76K | +46,137 | 0.00% |
| Citigroup Inc | 635,715 | 1.29% | $839.14K | – | 0.00% |
| Vanguard Capital Management LLC | 609,052 | 1.24% | $803.95K | −1,987 | 0.00% |
| Geode Capital Management, LLC | 539,312 | 1.10% | $712.09K | −4,531 | 0.00% |
| Vanguard Fiduciary Trust Co | 282,608 | 0.57% | $373.04K | +1,987 | 0.00% |
| UBS Group AG | 222,200 | 0.45% | $293.30K | – | 0.00% |
| Renaissance Technologies LLC | 205,400 | 0.42% | $271.13K | +15,500 | 0.00% |
| State Street Corp | 193,698 | 0.39% | $255.68K | – | 0.00% |
| Northern Trust Corp | 143,665 | 0.29% | $189.64K | +10,502 | 0.00% |
| Bank of New York Mellon Corp | 78,277 | 0.16% | $103.33K | – | 0.00% |
| Charles Schwab Investment Management Inc | 71,506 | 0.15% | $94.39K | – | 0.00% |
| Bridgeway Capital Management, LLC | 56,031 | 0.11% | $73.96K | – | 0.00% |
| SBI Securities Co., Ltd. | 51,479 | 0.10% | $67.95K | +6,603 | 0.00% |
| Dimensional Fund Advisors LP | 50,552 | 0.10% | $66.73K | – | 0.00% |
| Barclays PLC | 42,806 | 0.09% | $56.50K | −120,094 | 0.00% |
| Schonfeld Strategic Advisors LLC | 36,157 | 0.07% | $47.73K | −219 | 0.00% |
| Susquehanna International Group, Llp | 26,752 | 0.05% | $35.31K | −17,174 | 0.00% |
| Jane Street Group, LLC | 15,818 | 0.03% | $20.88K | −71,267 | 0.00% |
| Vanguard Global Advisers, LLC | 15,599 | 0.03% | $20.59K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 29 | 5M | 10.5% | 3 / 5 | 8 / 4 | 0M | 0M |
| Q1 2026 | 30 | 5M | 11.0% | 5 / 8 | 9 / 7 | 1M | 0M |
| Q4 2025 | 33 | 5M | 10.7% | 9 / 8 | 9 / 2 | 0M | 0M |
| Q3 2025 | 26 | 5M | 10.4% | 4 / 8 | 6 / 1 | 0M | 0M |
| Q2 2025 | 23 | 5M | 10.5% | 0 / 4 | 9 / 5 | 0M | 0M |
| Q1 2025 | 28 | 5M | 10.6% | 2 / 7 | 10 / 4 | 0M | 0M |
| Q4 2024 | 30 | 5M | 10.6% | 5 / 11 | 5 / 5 | 0M | 0M |
| Q3 2024 | 30 | 5M | 10.0% | 4 / 5 | 11 / 6 | 1M | 0M |
| Q2 2024 | 33 | 5M | 9.7% | 5 / 2 | 15 / 7 | 0M | 0M |
| Q1 2024 | 35 | 5M | 9.6% | 5 / 7 | 12 / 4 | 0M | 0M |
| Q4 2023 | 34 | 5M | 10.1% | 6 / 10 | 8 / 2 | 0M | 0M |
| Q3 2023 | 30 | 5M | 10.2% | 3 / 5 | 12 / 7 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
14 funds held MNOV in Q2 2026, 56% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of MNOV | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 609,052 | 1.24% | $803.95K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 255,141 | 0.52% | $346.99K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 158,976 | 0.32% | $209.85K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 87,575 | 0.18% | $119.10K | 0.00% | May 31, 2026 |
| Schwab Total Stock Market Index Fund | 71,506 | 0.15% | $95.10K | 0.00% | Jul 31, 2026 |
| Fidelity Series Total Market Index Fund | 68,406 | 0.14% | $93.03K | 0.00% | May 31, 2026 |
| Ultra-Small Company Market Fund | 50,247 | 0.10% | $66.33K | 0.04% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 25,966 | 0.05% | $35.31K | 0.00% | May 31, 2026 |
| Small Cap Core Fund | 13,894 | 0.03% | $18.34K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 10,525 | 0.02% | $13.89K | 0.01% | Jun 30, 2026 |
| LVIP Dimensional U.S. Core Equity 2 Fund | 6,693 | 0.01% | $8.83K | 0.00% | Jun 30, 2026 |
| AST Small-Cap Equity Portfolio | 4,930 | 0.01% | $6.51K | 0.00% | Jun 30, 2026 |
| JNL/DFA U.S. Small Cap Fund | 3,000 | 0.01% | $3.96K | 0.00% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 100 | 0.00% | $132 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Yuichi Iwaki | President and CEO | 1,091,933 | 2.22% | Jan 20, 2026 |
| Kazuko Matsuda | Chief Medical Officer | 322,996 | 0.66% | Jan 20, 2026 |
| Hideki Nagao | Director | 0 | – | Jun 25, 2026 |
| Carolyn Beaver | Director | – | – | Jun 25, 2026 |
| Nicole Lemerond | Director | – | – | Jun 25, 2026 |
| Opportunity Master Fund 3D | – | 4,862,047 | 9.88% | Sep 29, 2026 |
| Investment Partners Pte. Ltd. 3D | – | – | – | Sep 29, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Opportunity Master Fund 3D – | Sep 25, 2026 | Sale | −640,000 | $2.70 | $1.73M | 4,862,047 |
| Hideki Nagao Director | Nov 28, 2022 | Sale | −6,754 | $2.25 | $15.20K | 0 |
| Hideki Nagao Director | Nov 22, 2022 | Sale | −218 | $2.13 | $464 | 6,754 |
| Hideki Nagao Director | Nov 21, 2022 | Sale | −5,365 | $2.18 | $11.70K | 6,972 |
| Hideki Nagao Director | Nov 17, 2022 | Sale | −309 | $2.18 | $674 | 12,337 |
| Kazuko Matsuda Chief Medical Officer, Director | Aug 23, 2021 | Option exercise | +60,000 | $2.30 | $138.00K | 322,996 |
| Yuichi Iwaki President and CEO, Director | Jul 9, 2021 | Option exercise | +39,583 | $2.54 | $100.54K | 966,933 |
| Kazuko Matsuda Chief Medical Officer, Director | Jun 24, 2021 | Option exercise | +46,554 | $2.54 | $118.25K | 206,746 |
| Kazuko Matsuda Chief Medical Officer, Director | Jun 24, 2021 | Option exercise | +56,250 | $2.46 | $138.38K | 262,996 |
| Geoffrey OBrien Vice President | May 19, 2021 | Option exercise | +11,318 | $2.46 | $27.84K | 48,318 |
| Geoffrey OBrien Vice President | May 19, 2021 | Option exercise | +32,000 | $2.54 | $81.28K | 37,000 |
| Hideki Nagao Director | Mar 11, 2021 | Sale | −2,354 | $7.40 | $17.42K | 12,646 |
| Yuichi Iwaki President and CEO, Director | Feb 25, 2021 | Option exercise | +86,250 | $2.46 | $212.18K | 927,350 |
| Hideki Nagao Director | Sep 15, 2020 | Sale | −1,000 | $5.78 | $5.78K | 15,000 |
| Hideki Nagao Director | Aug 6, 2020 | Option exercise | +15,000 | $2.58 | $38.70K | 16,000 |
| Kazuko Matsuda Chief Medical Officer, Director | Jun 12, 2020 | Option exercise | +20,000 | $5.13 | $102.60K | 160,192 |
| Yuichi Iwaki President and CEO, Director | Apr 8, 2020 | Option exercise | +60,417 | $2.54 | $153.46K | 841,100 |
| Kazuko Matsuda Chief Medical Officer, Director | Apr 8, 2020 | Option exercise | +28,446 | $2.54 | $72.25K | 140,192 |
| Kazuko Matsuda Chief Medical Officer, Director | Mar 13, 2020 | Buy | +2,000 | $3.62 | $7.24K | 111,746 |
| Kazuko Matsuda Chief Medical Officer, Director | Mar 13, 2020 | Buy | +2,000 | $3.62 | $7.24K | 111,476 |
| Yuichi Iwaki President and CEO, Director | Mar 12, 2020 | Buy | +20,000 | $3.10 | $62.00K | 780,683 |
| Kazuko Matsuda Chief Medical Officer | Jun 12, 2019 | Option exercise | +37,000 | $4.80 | $177.60K | 109,457 |
| Hideki Nagao Director | May 13, 2019 | Option exercise | +1,000 | $2.77 | $2.77K | 1,000 |
| Masatsune Okajima VP and Head of Japanese Office | Feb 28, 2019 | Option exercise | +42,500 | $4.10 | $174.25K | 460,530 |
| Masatsune Okajima VP and Head of Japanese Office | Feb 28, 2019 | Option exercise | +80,000 | $4.10 | $328.00K | 418,030 |
| Masatsune Okajima VP and Head of Japanese Office | Feb 28, 2019 | Option exercise | +105,000 | $2.64 | $277.20K | 565,530 |
| Masatsune Okajima VP and Head of Japanese Office | Feb 28, 2019 | Option exercise | +120,000 | $3.91 | $469.20K | 835,530 |
| Masatsune Okajima VP and Head of Japanese Office | Feb 28, 2019 | Option exercise | +30,000 | $3.91 | $117.30K | 715,530 |
| Masatsune Okajima VP and Head of Japanese Office | Feb 28, 2019 | Option exercise | +15,000 | $3.24 | $48.60K | 580,530 |
| Masatsune Okajima VP and Head of Japanese Office | Feb 28, 2019 | Option exercise | +100,000 | $6.10 | $610.00K | 935,530 |
| Masatsune Okajima VP and Head of Japanese Office | Feb 28, 2019 | Option exercise | +105,000 | $7.00 | $735.00K | 1,040,530 |
| Masatsune Okajima VP and Head of Japanese Office | Feb 28, 2019 | Option exercise | +35,700 | $7.34 | $262.04K | 189,280 |
| Masatsune Okajima VP and Head of Japanese Office | Feb 28, 2019 | Option exercise | +85,000 | $2.54 | $215.90K | 274,280 |
| Masatsune Okajima VP and Head of Japanese Office | Feb 28, 2019 | Option exercise | +63,750 | $2.46 | $156.83K | 338,030 |
| Masatsune Okajima VP and Head of Japanese Office | Feb 28, 2019 | Option exercise | +105,000 | $3.09 | $324.45K | 685,530 |
| Masatsune Okajima VP and Head of Japanese Office | Jan 9, 2019 | Option exercise | +41,250 | $2.20 | $90.75K | 153,580 |
| Yuichi Iwaki President and CEO, Director | Jan 3, 2019 | Option exercise | +18,572 | $2.20 | $40.86K | 759,392 |
| Yuichi Iwaki President and CEO, Director | Mar 5, 2018 | Option exercise | +50,003 | $2.20 | $110.01K | 740,594 |
| Yuichi Iwaki President and CEO, Director | Jan 3, 2018 | Option exercise | +53,363 | $4.42 | $235.86K | 690,591 |
| Masatsune Okajima VP and Head of Japanese Office | Dec 12, 2017 | Option exercise | +48,000 | $4.42 | $212.16K | 108,941 |
| Yuichi Iwaki President and CEO, Director | Nov 2, 2017 | Option exercise | +21,067 | $4.42 | $93.12K | 637,228 |
| Yoshio Ishizaka Director | Aug 21, 2017 | Buy | +5,000 | $5.17 | $25.85K | 10,000 |
| Yutaka Kobayashi Director | May 15, 2017 | Buy | +1,000 | $5.60 | $5.60K | 25,000 |
| Yutaka Kobayashi Director | May 12, 2017 | Buy | +24,000 | $5.62 | $134.88K | 24,000 |
| Yutaka Kobayashi Director | Sep 15, 2016 | Buy | +11,800 | $6.44 | $75.99K | 81,800 |
| Yutaka Kobayashi Director | Sep 9, 2016 | Buy | +10,000 | $6.67 | $66.70K | 70,000 |
| Geoffrey OBrien Vice President | Jul 5, 2016 | Option exercise | +3,300 | $4.80 | $15.84K | 8,300 |
| Geoffrey OBrien Vice President | Jul 5, 2016 | Sale(10b5-1 plan) | −3,300 | $8.00 | $26.40K | 5,000 |
| Kazuko Matsuda Chief Medical Officer | Mar 14, 2016 | Option exercise | +800 | $3.56 | $2.85K | 62,003 |
| Masatsune Okajima VP and Head of Japanese Office | Mar 14, 2016 | Option exercise | +8,400 | $3.56 | $29.90K | 51,138 |
| Yutaka Kobayashi Director | Dec 10, 2014 | Buy | +12,000 | $3.54 | $42.48K | 60,000 |
| Yutaka Kobayashi Director | Nov 26, 2014 | Buy | +10,000 | $3.07 | $30.70K | 48,000 |
| Yutaka Kobayashi Director | Nov 20, 2014 | Buy | +13,000 | $3.19 | $41.47K | 38,000 |
| Yoshio Ishizaka Director | Nov 19, 2014 | Buy | +5,000 | $2.86 | $14.30K | 5,000 |
| Yutaka Kobayashi Director | Sep 11, 2014 | Buy | +10,000 | $2.95 | $29.50K | 25,000 |
| Yutaka Kobayashi Director | Sep 3, 2014 | Buy | +100 | $2.66 | $266 | 5,100 |
| Yutaka Kobayashi Director | Sep 3, 2014 | Buy | +5,000 | $2.63 | $13.15K | 5,000 |
| Yutaka Kobayashi Director | Sep 3, 2014 | Buy | +9,900 | $2.67 | $26.43K | 15,000 |
| Tatsuo Izumi Director | Dec 12, 2013 | Sale | −970 | $2.17 | $2.10K | 600,000 |
| Tatsuo Izumi Director | Dec 12, 2013 | Sale | −70,300 | $2.10 | $147.63K | 600,970 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of MediciNova's stock actually held short. Settlement fails (shares not delivered on time) peaked at 95,444 shares on Sep 18, 2026 over the last 90 days.
See a number that looks wrong?